Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice

Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice

Idiopathic pulmonary fibrosis (IPF) patients have a high risk of developing lung cancer, with few treatment options available. Pirfenidone, an antifibrotic agent approved for the treatment of IPF, has been demonstrated to suppress the TGFβ signaling and modulate the expression of immune-related gene...

Full description

Bibliographic Details
Main Authors: Wan Qin, Jun Zou, Yongbiao Huang, Chaofan Liu, Yalin Kang, Hu Han, Yang Tang, Long Li, Bo Liu, Weiheng Zhao, Xianglin Yuan
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
lung cancer
idiopathic pulmonary fibrosis
pd-l1 blockades
immune-checkpoint inhibitors
pirfenidone
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1824631

Internet

http://dx.doi.org/10.1080/2162402X.2020.1824631

Similar Items